---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-088684"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2022-08-10T23:59:59+00:00"
generated_at: "2026-06-24T01:25:04.272497+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# VYNE's FMX114 Phase 2a AD trial misses primary endpoint; shareholders reject reverse stock split

## Summary
- Phase 2a trial of FMX114 for mild-to-moderate atopic dermatitis did not meet primary endpoint (ADSI change at week 4, p=0.228).
- Mean ADSI reduction -60.62% for FMX114 vs -51.32% for vehicle; not statistically significant.
- CEO disappointed; company will evaluate pipeline and prioritization.
- Cash ~$43M as of June 30, 2022; $5M payment due Jan 2023 from MST franchise sale.
- Shareholders voted against reverse stock split (needed >28.9M votes, got 23.7M for).

## SEC filing metadata
- accession: 0001104659-22-088684
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2022-08-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465922088684/0001104659-22-088684-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465922088684/tm2222986d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-088684
- JSON: https://secwatch.observer/filing/0001104659-22-088684.json
- Plain text: https://secwatch.observer/filing/0001104659-22-088684.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.